XML 52 R42.htm IDEA: XBRL DOCUMENT
v3.23.3

Commitments and Contingencies - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | ---
Jul. 31, 2023 | Jan. 31, 2022 | Aug. 31, 2018 | Sep. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Sep. 30, 2018 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Loss (gain) on strategic investment |  |  |  |  |  |  |  | $ 5,109,000 | $ 1,998,000 |  |
Research and development |  |  |  | $ 156,963,000 |  | $ 81,336,000 |  | 284,878,000 | 285,837,000 |  |
Restricted cash |  |  |  | 5,770,000 |  | $ 5,770,000 |  | 5,770,000 | $ 5,770,000 | $ 5,770,000 | $ 5,770,000
Letter of Credit | Corporate Credit Card Program |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Restricted cash |  |  |  | 2,000,000 |  |  |  | 2,000,000 |  |  |
Letter of Credit | Fleet Program |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Restricted cash |  |  |  | 400,000 |  |  |  | 400,000 |  |  |
Stoke Therapeutics, Inc. [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements Upfront Consideration And Transaction Payment |  | $ 60,000,000 |  |  |  |  |  |  |  |  |
Mile stone payments payable |  | 907,500,000 |  |  |  |  |  |  |  |  |
Upfront consideration and transaction costs |  | $ 60,000,000 |  |  |  |  |  |  |  |  |
Collaboration Agreement, Cost Splits Description |  | For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits |  |  |  |  |  |  |  |  |
License Agreements | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Mile stone payments payable |  |  |  |  | $ 40,000,000 |  |  |  |  |  |
License Agreements | Neuren | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 100,000,000 |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Milestone payment as intangible asset |  |  |  |  | 40,000,000 |  |  |  |  |  |
PRV liability |  |  |  |  | $ 29,600,000 |  |  |  |  |  |
License Agreements | Neuren | Research and Development [Member] | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  | 100,000,000 |  |  | $ 10,000,000 |  |  |  |
License Agreements | Neuren | Development Commercialization and Sales Milestones |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment | 831,300 |  |  |  |  |  |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Mile stone payments payable |  |  |  | $ 2,800,000,000 |  |  |  | $ 2,800,000,000 |  |  |
Maximum | License Agreements | Neuren | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Mile stone payments payable | $ 426,300,000 |  | $ 455,000,000 |  |  |  |  |  |  |  |

X
- Definition Collaboration Agreement, Cost Splits Description + References No definition available. + Details
Name: | acad_CollaborationAgreementCostSplitsDescription
Namespace Prefix: | acad_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangements non-cash upfront payment. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsNonCashUpfrontPayment
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangements Upfront consideration and transaction Payment. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangements upfront license fee. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsUpfrontLicenseFee
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangements upfront payment. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsUpfrontPayment
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition PRV liability + References No definition available. + Details
Name: | acad_PrvLiability
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of realized and unrealized gain (loss) on investment. + References Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(c),9(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_GainLossOnInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details
Name: | us-gaap_RestrictedCashNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=acad_CorporateCreditCardProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=acad_FleetProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=acad_StokeTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=acad_LicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=acad_NeurenPharmaceuticalsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=acad_DevelopmentCommercializationAndSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |